Pediatric oncologist, sarcoma specialist, cancer researcher, and mom.
Joined April 2019
- Tweets132
- Following313
- Followers811
- Likes337
New work from the @JanewayLab reporting on a pediatric cancer patient cohort sequenced @DanaFarber with 95! different cancer diagnoses. So important to share data to learn about @RareCancer rdcu.be/dNt1d
Hooray to @JAMAOnc for focussing on rare cancer
Review describes the process of updating the global evidence-based consensus guideline on management of desmoid tumor, a rare and locally aggressive fibroblastic proliferation characterized by a variable and often unpredictable clinical course. ja.ma/4bbPw8b
Eirian Siegal-Botti from @count_me_in and @broadinstitute presenting @PECGSnetwork @the_osproject @AgentsMIB Factor conference. Thanks to @AgentsMIB and #osteosarcoma participants for your partnership in research.
@DanaFarber (inclusive of alums) at @AgentsMIB Factor #osteosarcoma meeting. Great science, company and fun!
#ASCO24 great session on #sarcoma biomarkers Riaz Gillani and David Shulman from @DanaFarber presented validation of prognostic impact of STAG2 loss in Ewing and elevated ctDNA in osteo. Congrats to investigators and discussants!!
#AACR24 so lucky to know many of the impressive cancer researchers named AACR Fellows of the Academy this morning. Congratulations!! @DavidMalkin1 and others it on X
Such important work you all do! Thank you.
Last night @CureSarcoma hosted the US patient advocacy groups for a dinner at #CTOS2023. It was wonderful to spend time with colleagues. Some could not make it and were missed. We are committed to working together on behalf of #sarcoma patients. #curesarcoma
So lucky to work at Dana-Farber. Congratulations Dr. Glimcher.
We are proud of @LGlimcherMD, president and CEO of @DanaFarber, for being named No. 5 on the list of the 2023 Top 100 Women-Led Businesses in Massachusetts.
Congratulations to her and the other nominees!
Fantastic #CTOS2023 meeting organized by this team!!!
The #ProgramCommittee of @ctosociety #CTOS2023. It’s been such a fun journey putting the programme together w/ an amazing team of individuals! We have 1 more day to go, but definitely not too early to thank @ashleighg, @GladdyLab, #MaureenO’Sullivan as well as Jennifer & Barbara and president #CarolSwallow for making things happen! 😃
Katie Janeway retweeted
‼️🆕Thrilled to share our groundbreaking work just published in @NatureMedicine 🔥
There is the unmet medical need to implement novel #ClinicalTrial designs in patients with #RareTumors to:
1) Facilitate clinical research🏥
2) Speed up drug approvals💊
➡️nature.com/articles/s41591-0…
Great meeting @UNM hosted by @CherylWillmanMD discussing patient engagement in cancer genome research with this outstanding osproject.org and lmsproject.org team.
Katie Janeway retweeted
there is no second mode any more in the classically described 65+ age group!
The 3d graph shows how the incidence rate in the post-adolescence period has become emphatically flat!
ALT Distribution of Osteosarcoma of long bones of the lower limbs based on age at diagnosis from SEER data 1975-2020: Total incidence of Osteosarcoma of the long bones of the lower limbs based on Surveillance, Epidemiology, and End Results (SEER) 8 database, 1975-2020, by age at initial diagnosis. The number of tumors was totaled in each age group across the 46-year span.
ALT Incidence Rate of Osteosarcoma of Long Bones of Lower Limbs from SEER data 1975-2020: 3D Representation of the Incidence Rate of Osteosarcoma of the long bones of the lower limbs based on Surveillance, Epidemiology, and End Results (SEER) 8 database, 1975-2020, by age at initial diagnosis and year of diagnosis. The change in color to a lighter purple corresponds to an increased incidence rate of osteosarcoma reported in that age group that particular calendar year.
It is the anniversary of our patient partnered osteosarcoma project — osproject.org — creating a clinico-genomic database for the research community to drive discovery. Patients enroll online. Consider referring your patients during #childhoodcancerawareness month
So happy to see work done by Maeve Smart @JanewayLab about Covid-19 infection in pediatric cancer patients at #ASCO2023
It’s been an honor to be an associate editor @JCOPO_ASCO. Passing the pediatric torch to @LaetschTheodore
Taking on my first @ASCO journal #AssociateEditor role w @JCOPO_ASCO. What a TERRIFIC editorial board led by #DrJamesFord @StanfordCancer w terrific colleagues like @thenasheffect, @HHampel1, @christine_lovly, @stacywgray @janeway_MD & so many others. Several Special Series coming your way soon - reach out if you have questions re: submitting! #ASCO23
Great to see @OSInstitute and @quadwfoundation leaders in Chicago @ASCO2023 (@marykclark was the photographer)
The OSI is attending #ASCO2023 this week in Chicago, IL along with global cancer experts to discover the latest innovations in cancer research and education. Learn more at conferences.asco.org.
Katie Janeway retweeted
The OSI is attending #ASCO2023 this week in Chicago, IL along with global cancer experts to discover the latest innovations in cancer research and education. Learn more at conferences.asco.org.
great to see nice work from collaborators at the #ASCO2023 sarcoma poster session. @jalivingston_md
💫Poster Board 483 #sarcoma
Superstar @MNakazawa8 and @jalivingston_md presenting work from @MDAndersonNews:
Identification of a subset of DDR deficient #LMS with loss of RNase H2
⚠️therapeutic implications
‼️potentially targetable
Excited to present on our patient partnered research on osteosarcoma and leiomyosarcoma next month!!
This Post is from an account that no longer exists. Learn more
Looking forward to hearing Susanne Gatz and @JGladeBender speak at 11:45 AM today @AACR2023 clinical trials plenary.